A relatively new class of cancer-fighting drugs, immune checkpoint inhibitors (ICIs), are proving very effective in targeting tumors. They are also, however, associated with some potentially serious adverse skin reactions. Unfortunately, these same side effects may be a good sign that the drugs are working. So discontinuation is not a decision to be made lightly. A new study provides useful guidance on how to manage most of these dermatologic reactions and preserve the course of cancer therapy in most cases.
ICIs are monoclonal antibodies that offer promise in treating a growing number of cancers by unleashing the immune system—which is also the reason for their immune-mediated adverse events (AEs). These include non-small cell and small cell lung cancers, Hodgkin lymphoma, bladder cancer, renal cell carcinoma, melanoma, and Merkel cell carcinoma.[1]
In light of the expanding role for these agents, it is essential that we learn to recognize both common and less common but severe AEs associated with these powerful drugs. Although bothersome skin reactions are protean, these more severe reactions can be life-threatening and can include gastrointestinal (colitis), liver (hepatitis), or cutaneous toxicities.[2,3]
Cutaneous AEs occur in up to one half of patients taking ICIs, making this one of the most common complications of these agents.
